Drug Trial Radar · NCT06497556
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
338
Actual
Start
Sep 23, 2024
Primary completion
May 19, 2026
Study completion Nov 30, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Jul 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions
- Non-Small Cell Lung Cancer
- KRAS G12C Lung Cancer
Interventions
DivarasibDrug
Divarasib will be administered orally QD
SotorasibDrug
Sotorasib will be administered orally QD
AdagrasibDrug
Adagrasib will be administred orally BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 4 years
Locations
151 sites in 26 countries. Site status is shown where the registry gives one.
Banner Health MD Anderson AZ
Gilbert, Arizona
Los Angeles Cancer Network
Los Angeles, California
UCLA Hematology / Oncology Clinic
Los Angeles, California
University of California, San Francisco
San Francisco, California
Yale Cancer Center
New Haven, Connecticut
University of Miami
Miami, Florida
Florida Cancer Specialists - North;725 6th Ave South (St. Petersburg)
St. Petersburg, Florida
University of Chicago Medical Center
Chicago, Illinois
New England Cancer Specialists
Westbrook, Maine
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan
Minnesota Oncology Edina
Edina, Minnesota
Columbia University Medical Center
New York, New York
Taylor Cancer Research Center
Maumee, Ohio
Oncology Associates of Oregon, P.C
Eugene, Oregon
Oregon Health & Science University
Portland, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Allegheny Cancer Center
Pittsburgh, Pennsylvania
Tennessee Oncology, PLLC - Chattanooga
Chattanooga, Tennessee
Baptist Clinical Research Institute
Memphis, Tennessee
Tennessee Oncology
Nashville, Tennessee
JPS Health Network
Fort Worth, Texas
MD Anderson Cancer Center
Houston, Texas
Texas Oncology - Northeast Texas
Longview, Texas
Hospital Britanico
Buenos Aires, Argentina
Centro Oncologico Korben
Ciudad Autonoma Buenos Aires, Argentina
Liverpool Hospital
Liverpool, New South Wales, Australia
GenesisCare North Shore
St Leonards, New South Wales, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Lyell McEwin Hospital
Elizabeth Vale, South Australia, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Krankenhaus Nord - Klinik Floridsdorf
Vienna, Austria
AZORG Campus Aalst-Moorselbaan
Aalst, Belgium
UZ Brussel
Brussels, Belgium
Cliniques Universitaires St-Luc
Brussels, Belgium
UZ Antwerpen
Edegem, Belgium
Jessa Zkh (Campus Virga Jesse)
Hasselt, Belgium
CHU de Liège (Sart Tilman)
Liège, Belgium
CHU UCL Mont-Godinne
Mont-godinne, Belgium
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.